Dr. Vasella: Novartis is a global Swiss-American Healthcare company headquartered in Basel, Switzerland. Our core businesses are in innovative branded pharmaceuticals, generics, OTC and animal health as well as consumer health products including eye-care and baby care. Pharmaceuticals currently represent 64% of our business, based on sales, with the U.S. as its biggest market. We employ about 78,200 people and operate in over 140 countries around the world. We are focused on innovation with heavy investments into R&D in order to satisfy the needs of patients and communities we serve.
TWST: What is the breakdown of sales per business unit and geography?
Dr. Vasella: As of Q2 of this year our pharmaceutical division had sales of USD 7.6 billion, achieving double-digit growth of 18%. The generics business, which was recently re-branded as Sandoz, had a sales leap to USD 1463 million, due to strong performance in the US and the consolidation of Lek which we acquired earlier this year. Our over-the-counter medicines and animal health businesses reached sales of UDS 830 million and USD 339 million respectively. For the first half of the year sales in the medical nutrition unit climbed to USD 401 million, the infant and baby division achieved sales of USD 664 million, and CIBA Vision sales increased to USD 627 million.
Geographically the US is our largest market with 42% of our sales generated in this region. Europe accounts for 36% of our sales, followed by Asia, Australia, and Africa with 15% and the rest of the Americas with 7%.
Tickers included in this excerpt: NVS
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.